Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas

Status
Active
Cancer Type
Leukemia
Lymphoma
Non-Hodgkin Lymphoma
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCD ID
NCT02732275
Protocol IDs
DS3201-A-J101 (primary)
NCI-2019-00366
Study Sponsor
Daiichi Sankyo Co., Ltd.

Summary

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research. Adults with non-Hodgkin lymphoma (NHL) might be able to join this study if their disease: - has come back after remission - is not responding to current treatment This study has two parts: 1. Dose Escalation is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. 2. Dose Expansion is to: - find out how effective DS-3201b is for rare types of NHL - collect additional safety data
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.